Cited In for PMID: 28233509

Year	Number of Results
2017	3
2018	13
2019	11
2020	14
2021	11
2022	14
2023	9

1

Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Gold B, Nathan C. Gold B, et al. Microbiol Spectr. 2017 Jan;5(1):10.1128/microbiolspec.TBTB2-0031-2016. doi: 10.1128/microbiolspec.TBTB2-0031-2016. Microbiol Spectr. 2017. PMID: 28233509 Free PMC article. Review.

2

Drug-Tolerant Mycobacterium tuberculosis Adopt Different Survival Strategies in Alveolar Macrophages of Patients with Pulmonary Tuberculosis.

Ufimtseva EG, Eremeeva NI. Ufimtseva EG, et al. Int J Mol Sci. 2023 Oct 6;24(19):14942. doi: 10.3390/ijms241914942. Int J Mol Sci. 2023. PMID: 37834390 Free PMC article.

3

Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We Stand.

Lanni A, Iacobino A, Fattorini L, Giannoni F. Lanni A, et al. Microorganisms. 2023 Jun 6;11(6):1511. doi: 10.3390/microorganisms11061511. Microorganisms. 2023. PMID: 37375013 Free PMC article. Review.

4

Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens.

Budak M, Cicchese JM, Maiello P, Borish HJ, White AG, Chishti HB, Tomko J, Frye LJ, Fillmore D, Kracinovsky K, Sakal J, Scanga CA, Lin PL, Dartois V, Linderman JJ, Flynn JL, Kirschner DE. Budak M, et al. PLoS Comput Biol. 2023 Jun 15;19(6):e1010823. doi: 10.1371/journal.pcbi.1010823. eCollection 2023 Jun. PLoS Comput Biol. 2023. PMID: 37319311 Free PMC article.

5

Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes.

Temrikar ZH, Kodidela S, Kumar S, Liu J, Robertson GT, Lee RE, Hickey AJ, Gonzalez-Juarrero M, Meibohm B. Temrikar ZH, et al. Tuberculosis (Edinb). 2023 May;140:102342. doi: 10.1016/j.tube.2023.102342. Epub 2023 Apr 20. Tuberculosis (Edinb). 2023. PMID: 37120915

6

A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.

Sarathy JP, Xie M, Jones RM, Chang A, Osiecki P, Weiner D, Tsao WS, Dougher M, Blanc L, Fotouhi N, Via LE, Barry CE 3rd, De Vlaminck I, Sherman DR, Dartois VA. Sarathy JP, et al. mBio. 2023 Apr 25;14(2):e0059823. doi: 10.1128/mbio.00598-23. Epub 2023 Apr 5. mBio. 2023. PMID: 37017524 Free PMC article.

7

Mycobacterium abscessus DosRS two-component system controls a species-specific regulon required for adaptation to hypoxia.

Simcox BS, Tomlinson BR, Shaw LN, Rohde KH. Simcox BS, et al. Front Cell Infect Microbiol. 2023 Mar 9;13:1144210. doi: 10.3389/fcimb.2023.1144210. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 36968107 Free PMC article.

8

Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response.

Peters JS, McIvor A, Papadopoulos AO, Masangana T, Gordhan BG, Waja Z, Otwombe K, Letutu M, Kamariza M, Sterling TR, Bertozzi CR, Martinson NA, Kana BD. Peters JS, et al. Front Cell Infect Microbiol. 2023 Jan 12;12:1064148. doi: 10.3389/fcimb.2022.1064148. eCollection 2022. Front Cell Infect Microbiol. 2023. PMID: 36710965 Free PMC article.

9

Identification of 2-Amino Benzothiazoles with Bactericidal Activity against Mycobacterium tuberculosis.

Bonnett S, Jee JA, Chettiar S, Ovechkina Y, Korkegian A, Greve E, Odingo J, Parish T. Bonnett S, et al. Microbiol Spectr. 2023 Feb 14;11(1):e0497422. doi: 10.1128/spectrum.04974-22. Epub 2023 Jan 23. Microbiol Spectr. 2023. PMID: 36688635 Free PMC article.

10

Advances in the design of combination therapies for the treatment of tuberculosis.

Larkins-Ford J, Aldridge BB. Larkins-Ford J, et al. Expert Opin Drug Discov. 2023 Jan;18(1):83-97. doi: 10.1080/17460441.2023.2157811. Epub 2022 Dec 28. Expert Opin Drug Discov. 2023. PMID: 36538813 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

68 results

Results by year